Feline CMOP for Intermediate- to Large-Cell Lymphoma

cyclophosphamide, mitoxantrone, vincristine and prednisolone is covered as multi-agent feline lymphoma chemotherapy protocol, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Multi-agent feline lymphoma chemotherapy protocol. Cyclophosphamide, mitoxantrone, vincristine and prednisolone. CMOP replaces doxorubicin in CHOP with mitoxantrone; it is not COP and is not a generic label for any four-drug lymphoma plan.

Cyclophosphamide, mitoxantrone, vincristine and prednisolone. CMOP replaces doxorubicin in CHOP with mitoxantrone; it is not COP and is not a generic label for any four-drug lymphoma plan.

CMOP combines DNA alkylation, topoisomerase inhibition, microtubule disruption and glucocorticoid effects. Mitoxantrone and doxorubicin share some clinical roles but differ in vesicant potential, pharmacology and evidence; they are not simple milligram-for-milligram substitutes.

A 2025 multi-institutional Australian retrospective study compared first-line CMOP with CHOP in cats with intermediate- to large-cell lymphoma. CMOP may be considered when its administration and risk profile fit the patient and service, but tumour location, grade, stage, comorbidity and owner goals remain central.

A 2025 multi-institutional Australian retrospective study compared first-line CMOP with CHOP in cats with intermediate- to large-cell lymphoma. CMOP may be considered when its administration and risk profile fit the patient and service, but tumour location, grade, stage, comorbidity and owner goals remain central.

Specialist combination of intravenous and oral medicines

The study found no statistically significant difference in measured outcomes between its cohorts, but retrospective non-randomised data cannot establish universal equivalence or non-inferiority. It does not apply to feline small-cell lymphoma, every anatomic lymphoma form or cats who would have been excluded from treatment.

Expected risks include marrow suppression, infection, gastrointestinal effects, sterile haemorrhagic cystitis from cyclophosphamide, vincristine-associated gastrointestinal or neurologic toxicity, infusion reactions and local tissue injury. Prednisolone has metabolic and immunosuppressive effects.

Other marrow suppressants, liver- or kidney-active medicines, prior anthracyclines, previous glucocorticoids and unreviewed supplements require reconciliation. A change in one component or schedule creates a modified protocol whose evidence may differ.

CMOP is not an approved feline combination product. Component use may be extra-label and must comply with local veterinary prescribing law. US extra-label use requires a valid VCPR and AMDUCA conditions.

The cited cohort came from Australian referral centres; that study location does not create APVMA approval. Component status and extra-label rules must be checked in the treatment country.

Confirm lymphoma pathology and grade, anatomic distribution, FeLV/FIV context where clinically relevant, baseline blood counts and organ function. The team plans blood-count and organ surveillance, urinalysis when indicated, objective response assessment and adverse-event thresholds. Fever, breathing change, painful urination, collapse or severe gastrointestinal signs require prompt review.